ALNY:NSD-Alnylam Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 125.45

Change

-0.21 (-0.17)%

Market Cap

USD 14.60B

Volume

0.51M

Average Target Price

USD 158.07 (+26.00%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.alnylam.com

Address : 675 West Kendall Street, Cambridge, MA, United States, 02142

Employees : 1,323

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.59

52 Week High : 167.33

Short Ratio : 6.90

52 Week Low : 84.97

Shorted Shares : 3,587,593

200 Day Moving Average : 139.17

Shorted Shares Previous Month : 3,385,202

50 Day Moving Average : 133.74

Shares Held By Insiders : 8.140000000000001%

Short Percentage : 3.00%

Shares Held by Institutions : 94.62%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.60 (+0.74%)

 USD56.30B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+2.21 (+0.44%)

 USD54.00B 20.76 16.02
MRNA Moderna, Inc

+10.62 (+10.78%)

 USD39.00B N/A N/A
SGEN Seagen Inc

+0.82 (+0.50%)

 USD29.47B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

-0.18 (-0.15%)

 USD26.94B 28.36 26.40
RPRX Royalty Pharma plc

+1.39 (+3.51%)

 USD24.75B 23.05 9.48
BNTX BioNTech SE

+3.09 (+3.03%)

 USD24.53B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.98 (+3.11%)

 USD23.81B N/A N/A
GMAB Genmab A/S

+0.68 (+1.93%)

 USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALNY

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.20 (+0.40%)

 USD0.03B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

-0.08 (-0.23%)

 USD0.02B
SCHM Schwab U.S. Mid-Cap ETF 0.00 % 0.04 %

-0.24 (-0.37%)

 USD6.47B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

-0.16 (-0.23%)

 USD0.45B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

+0.40 (+0.75%)

 USD0.10B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

-0.27 (-0.69%)

 USD0.03B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.20 %

-0.07 (-0.83%)

 USD0.08B
IWSZ:LSE iShares Edge MSCI World S.. 0.00 % 0.30 %

-0.20 (-0.52%)

 USD0.61B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.93% 55% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.93% 54% F 59% F
Trailing 12 Months  
Capital Gain 6.71% 47% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.71% 46% F 53% F
Trailing 5 Years  
Capital Gain 16.83% 69% D+ 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.83% 69% D+ 44% F
Average Annual (5 Year Horizon)  
Capital Gain 32.44% N/A N/A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.44% N/A N/A 86% B
Risk Return Profile  
Volatility (Standard Deviation) 77.22% N/A N/A 12% F
Risk Adjusted Return 42.01% N/A N/A 64% D
Market Capitalization 14.60B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.92 13% F 10% F
Price / Cash Flow Ratio -52.43 93% A 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -63.14% 52% F 18% F
Return on Invested Capital -67.88% 45% F 14% F
Return on Assets -19.92% 66% D 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.30 33% F 19% F
Short Percent 4.26% 65% D 44% F
Beta 1.59 46% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.